Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
2024; Elsevier BV; Volume: 25; Issue: 9 Linguagem: Inglês
10.1016/s1470-2045(24)00318-8
ISSN1474-5488
AutoresJean-Yves Blay, Quentin Devin, Florence Duffaud, Maud Toulmonde, Nelly Firmin, Olivier Collard, Emmanuelle Bompas, Benjamin Verret, Isabelle Ray‐Coquard, Sébastien Salas, Clémence Hénon, Charles Honoré, Mehdi Brahmi, Armelle Dufresne, Marc Pracht, Alice Hervieu, Nicolas Penel, François Bertucci, María Rios, Esma Sâada-Bouzid, Pauline Soibinet, David Pérol, Sylvie Chabaud, Antoîne Italiano, Axel Le Cesne,
Tópico(s)Gastrointestinal disorders and treatments
ResumoThe long-term impact of tyrosine kinase inhibitor (TKI) discontinuation on resistance and survival in patients with advanced gastrointestinal stromal tumours (GIST) is unclear. We report the exploratory long-term outcomes of patients with advanced GIST stopping imatinib in the BFR14 trial.
Referência(s)